Natural Products Derived from Marine Sponges with Antitumor Potential against Lung Cancer: A Systematic Review Ortigosa Palomo, Alba Quiñonero Muñoz, Francisco José Ortiz Quesada, Raúl Sarabia, Francisco Prados Salazar, José Carlos Melguizo Alonso, Consolación Marine sponge Bioactive compounds Antitumor Non-small-cell lung cancer (NSCLC), the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide, has been extensively investigated in the last decade in terms of developing new therapeutic options that increase patient survival. In this context, marine animals are a source of new, interesting bioactive molecules that have been applied to the treatment of different types of cancer. Many efforts have been made to search for new therapeutic strategies to improve the prognosis of lung cancer patients, including new bioactive compounds and cytotoxic drugs from marine sponges. Their antitumoral effect can be explained by several cellular and molecular mechanisms, such as modulation of the cell cycle or induction of apoptosis. Thus, this systematic review aims to summarize the bioactive compounds derived from marine sponges and the mechanisms by which they show antitumor effects against lung cancer, exploring their limitations and the challenges associated with their discovery. The search process was performed in three databases (PubMed, SCOPUS, andWeb of Science), yielding a total of 105 articles identified in the last 10 years, and after a screening process, 33 articles were included in this systematic review. The results showed that these natural sponge-derived compounds are a valuable source of inspiration for the development of new drugs. However, more research in this field is needed for the translation of these novel compounds to the clinic. 2024-05-15T10:04:33Z 2024-05-15T10:04:33Z 2024-02-23 info:eu-repo/semantics/article Ortigosa-Palomo, A.; Quiñonero, F.; Ortiz, R.; Sarabia, F.; Prados, J.; Melguizo, C. Natural Products Derived from Marine Sponges with Antitumor Potential against Lung Cancer: A Systematic Review. Mar. Drugs 2024, 22, 101. https://doi.org/10.3390/md22030101 https://hdl.handle.net/10481/91810 10.3390/md22030101 eng http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional MDPI